Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Juvenile Idiopathic Arthritis (Apr 2019)

Posted by Matt Breese on Apr 12, 2019

Find me on:

According to our recent payer coverage analysis for juvenile idiopathic arthritis treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for juvenile idiopathic arthritis treatments shows that under the pharmacy benefit, almost 70% of the lives under commercial formularies are covered with utilization management restrictions. 

MMIT-Reality Check-Juvenile Idiopathic Arthritis_2Q2019Data snapshot as of Q2 2019

Trends: There are multiple biosimilars in this class that have been approved by the FDA but will not launch until sometime between 2021 and 2023. Via AIS Health.

To read the full Reality Check on Juvenile Idiopathic Arthritis treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing